Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Quanex Building Products Corporation during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Quanex securities between December 12, 2024, and September 5, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 18, 2025 [3][6]. - The lawsuit claims that Quanex made false and misleading statements regarding its operations, particularly concerning the maintenance of tooling and equipment at its Tyman Mexico facility, which were significantly underinvested [5]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering substantial amounts for investors [4]. - The firm has been recognized for its achievements in securities class action settlements, including a notable settlement against a Chinese company and ranking highly in the number of settlements achieved [4]. Group 3: Case Specifics - The lawsuit alleges that Quanex's tooling and equipment conditions had degraded to near catastrophic levels, leading to significant costs and delays in expected benefits from the Tyman integration [5]. - It is claimed that Quanex had previously identified these issues, and the positive statements made by the defendants about the company's business were materially misleading [5].

Core Viewpoint - The Schall Law Firm is investigating potential securities law violations by Ardent Health, Inc., focusing on misleading statements and undisclosed information that may have affected investors [2]. Financial Impact - Ardent Health, Inc. reported a $43 million reduction in revenue due to accounting changes and a $54 million increase in professional liability reserves in its Q3 2025 financial results [2]. - Following this announcement, Ardent's shares fell nearly 34% the next day [2]. Legal Action - The Schall Law Firm is encouraging shareholders who suffered losses to participate in the investigation and discuss their rights [3].

Core Viewpoint - Stride, Inc. is facing a securities fraud class action lawsuit due to allegations of misleading statements and omissions regarding its products and services, which have resulted in significant financial losses for investors [3][4][5]. Summary by Sections Lawsuit Details - The lawsuit is on behalf of investors who purchased Stride securities from October 22, 2024, to October 28, 2025, alleging that the company inflated enrollment numbers and cut staff costs beyond statutory limits while ignoring compliance requirements [3]. Allegations and Impact - A complaint was filed by the Gallup-McKinley County Schools Board of Education against Stride, alleging fraud and deceptive practices, including retaining "ghost students" to secure state funding, which led to a significant drop in share price by approximately 11.7% [4]. - On October 28, 2025, Stride reported that "poor customer experience" resulted in an estimated 10,000-15,000 fewer enrollments, causing a dramatic decline in share price by approximately 54.4% [5]. Investor Actions - Investors who suffered losses on their Stride investments have until January 12, 2026, to request lead plaintiff appointment in the class action lawsuit [2].

Core Points - A class action lawsuit has been filed against Perrigo Company plc for alleged securities fraud and unlawful business practices [1] - Investors who purchased Perrigo securities during the Class Period can apply to be Lead Plaintiff by January 16, 2026 [2] - Perrigo reported significant financial challenges, including a 50% decline in earnings per share for fiscal year 2023 due to remediation costs in its infant formula business [2] - The company's stock price has experienced significant declines following negative earnings reports and strategic announcements, including a drop of 25.2% to close at $15.10 per share on November 5, 2025, after announcing a strategic review of its infant formula business [3] Financial Performance - For fiscal year 2023, Perrigo incurred one-time cash costs of $35 million to $45 million related to production issues in its infant formula business [2] - The adjusted gross profit for the second quarter ended June 28, 2025, decreased by $30 million, or 6.9%, attributed to production variability in infant formula [3] - The stock price fell by $4.87 per share (15.14%) on February 27, 2024, and by $3.28 per share (9.8%) on May 7, 2024, following negative earnings reports [2][3]

Core Viewpoint - Blue Owl Capital Inc. is under investigation for potential violations of federal securities laws following a report about blocking redemptions in one of its private credit funds, which may lead to significant losses for investors [1][2]. Group 1: Company Actions - Blue Owl Capital has blocked redemptions in its early private credit fund as it merges with a larger vehicle, which could result in investors permanently losing the ability to redeem cash at the fund's Net Asset Value (NAV) [2]. - After the announcement of the merger, Blue Owl's stock price experienced a decline of over 6% during intraday trading on November 17, 2025 [3]. Group 2: Financial Implications - Investors in Blue Owl Capital Corporation II will have to exchange their shares for publicly traded Blue Owl Capital Corporation shares, which are currently trading at a 20% discount to the fund's NAV [2].

Core Points - Inspire Medical Systems, Inc. is facing a class action lawsuit due to alleged securities fraud related to the poor performance of its new sleep apnea device, Inspire V, which has been delayed in launch and has seen poor demand [2][4]. - The company significantly reduced its 2025 earnings guidance by over 80%, from a range of $2.20 to $2.30 per share down to $0.40 to $0.50 per share [2][3]. Company Performance - On August 4, 2025, Inspire disclosed issues with the launch of Inspire V, including inadequate training for treatment centers, software update delays, and excess inventory leading to poor demand [2][4]. - Following the announcement, Inspire's stock price dropped by $42.04, or 32.4%, closing at $87.91 per share on August 5, 2025, impacting investors negatively [3]. Legal Proceedings - The class action lawsuit alleges that the company made materially false and misleading statements regarding its business operations and prospects during the class period from August 6, 2024, to August 4, 2025 [4][5]. - Investors who purchased Inspire common stock during the class period are encouraged to file a lead plaintiff motion by January 5, 2026 [5].

Core Viewpoint - Telix Pharmaceuticals Limited is facing a class action lawsuit due to alleged securities fraud, with a deadline for investors to file a lead plaintiff motion by January 9, 2026 [1][5]. Summary by Sections Company Developments - On July 22, 2025, Telix disclosed receiving a subpoena from the U.S. Securities and Exchange Commission (SEC) regarding its disclosures related to prostate cancer therapeutic candidates, leading to a stock price drop of $1.70, or 10.4%, closing at $14.58 on July 23, 2025 [2]. - On August 28, 2025, Telix announced it received a Complete Response Letter (CRL) from the FDA concerning its Biologics License Application (BLA) for TLX250-CDx, which identified deficiencies in the Chemistry, Manufacturing, and Controls (CMC) package. This announcement caused the stock price to fall by $1.95, or 16.1%, closing at $10.15 on the same day [3]. Allegations in the Lawsuit - The class action complaint alleges that during the Class Period, Telix's management made materially false and misleading statements and failed to disclose adverse facts about the company's business and prospects. Specific allegations include: 1. Overstating the progress made on prostate cancer therapeutic candidates. 2. Overstating the quality of Telix's supply chain and partners. 3. Misleading investors regarding the company's business and operational prospects [4].

Core Viewpoint - An investigation has been announced regarding Blue Owl Capital Inc. for potential violations of federal securities laws, indicating possible legal issues that may affect investors [1]. Company Summary - Blue Owl Capital Inc. is currently under scrutiny for alleged violations of federal securities laws, which may have resulted in financial losses for its investors [1]. - The Law Offices of Howard G. Smith are reaching out to investors who have suffered losses in Blue Owl Capital Inc. to discuss potential claims for recovery [1].

Core Viewpoint - A class action lawsuit has been filed against Perrigo Company plc for securities fraud, alleging that the company made misleading statements regarding its infant formula business and failed to disclose significant operational issues [1][11]. Summary by Sections Lawsuit Details - The lawsuit was filed in the U.S. District Court for the Southern District of New York on behalf of shareholders who acquired Perrigo securities between February 27, 2023, and November 4, 2025 [1]. - Plaintiffs are pursuing claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1]. Financial Performance and Issues - In November 2022, Perrigo acquired Nestlé's Gateway infant formula plant and the rights to the Good Start brand for $170 million [3]. - On February 27, 2024, Perrigo reported a 50% decline in earnings per share compared to the previous year, attributing this to remediation costs in the infant formula business, which were estimated to be an additional $35 million to $45 million [4]. - Following this announcement, Perrigo's share price fell by $4.87, or 15.14%, closing at $27.30 [5]. - On May 7, 2024, the company reported a 34.5% decrease in net sales for the first quarter, with gross margin declining by 90 basis points [6]. - The share price dropped by $3.28, or 9.8%, to close at $30.15 on the same day [7]. - On August 6, 2025, Perrigo disclosed that production issues led to scrapping approximately $11 million of inventory, resulting in a share price decline of $3.01, or 11.31%, to close at $23.61 [8]. - On November 5, 2025, Perrigo announced a strategic review of its infant formula business and slashed its fiscal year 2025 outlook, cutting net sales growth guidance to -2.5% to -3% from a previous expectation of 0% to 3% [9]. - The stock price fell by $5.09, or 25.2%, to close at $15.10 on the same day [10]. Allegations in the Lawsuit - The lawsuit alleges that Perrigo's management made materially false and misleading statements and failed to disclose adverse facts about the infant formula business, including: 1. Significant underinvestment in maintenance and operational improvements [11]. 2. The need for substantial capital expenditures beyond stated estimates for remediation [11]. 3. Manufacturing deficiencies in the infant formula facility [11]. 4. Overstated financial results, including earnings and cash flow [11]. 5. Misleading positive statements regarding the company's business and prospects [11].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. for securities fraud following a significant stock drop due to alleged violations of federal securities laws [2][4]. Company Overview - Inspire Medical Systems, Inc. specializes in developing and manufacturing implantable medical devices for the treatment of sleep apnea, with its latest product being the Inspire V, which received FDA approval on August 2, 2024 [5]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, which was supposed to meet high demand. However, the company failed to adequately prepare clinicians and payors, leading to significant delays in adoption [6][7]. - The launch of Inspire V faced an "elongated timeframe," resulting in a reduction of the 2025 earnings per share guidance by over 80%. Contributing factors included incomplete training at implanting centers and poor demand due to excess inventory of older devices [8]. Stock Performance - Following the announcement of the delays, Inspire's stock price plummeted by $42.04 per share, a decrease of more than 32%, dropping from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [9].